Alectinib 150mg Capsules

Alectinib 150mg Capsules is a highly selective and potent next-generation tyrosine kinase inhibitor (TKI) specifically engineered to target Anaplastic Lymphoma Kinase (ALK) positive non-small cell lung cancer (NSCLC). This medication functions by binding to the ATP-binding site of the ALK receptor, effectively silencing the oncogenic signaling pathways—such as PI3K/AKT/mTOR and RAS/RAF/MEK/ERK—that drive the uncontrolled growth and survival of malignant cells. Unlike earlier inhibitors, Alectinib was meticulously designed to be a “poor substrate” for P-glycoprotein, an efflux pump in the blood-brain barrier. This unique molecular property allows the drug to achieve high concentrations within the central nervous system (CNS), making it exceptionally effective at both treating and preventing brain metastases. Discover how this professional pharmaceutical intervention provides the ultimate clinical strategy for long-term disease control, offering a superior first-line treatment that significantly extends progression-free survival compared to traditional therapies.

The 150mg capsule is the standardized dosage unit for the recommended regimen of 600mg twice daily. This requires the patient to take four capsules in the morning and four in the evening. While the “pill burden” may seem high, this specific concentration allows for precise dose modifications (e.g., reducing to 450mg or 300mg twice daily) if the patient experiences adverse effects. The capsule formulation is designed to be taken with food, which significantly increases the systemic absorption and bioavailability of the active ingredient, ensuring consistent therapeutic levels are maintained in the blood.

Indications and Uses of Alectinib 150mg Capsules

Alectinib 150mg Capsules is commonly prescribed for the specialized management of the following malignancy:

• ALK-Positive Metastatic NSCLC: It is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. It is the preferred first-line therapy for newly diagnosed patients and is also used for those who have progressed on or are intolerant to crizotinib.

Key Features of Alectinib 150mg Capsules

• Superior CNS Penetration: The primary feature of Alectinib 150mg Capsules is its ability to bypass the blood-brain barrier’s efflux pumps, providing robust protection against brain metastases.
• Next-Generation Selectivity: It targets ALK more selectively than first-generation TKIs, resulting in a generally more favorable side-effect profile.
• Extended Survival: Clinical trials have demonstrated that it significantly delays disease progression compared to standard chemotherapy and earlier ALK inhibitors.
• Precision Titration: The 150mg strength allows for incremental dose adjustments to manage toxicity without compromising the entire therapeutic effect.
• Oral Convenience: As a self-administered oral therapy, it allows patients to manage their treatment at home rather than in an infusion center.

Storage for Alectinib 150mg Capsules

To preserve the pharmacological stability and ultimate potency of the active ingredients, Alectinib 150mg Capsules should be stored at controlled room temperature, typically between 20°C and 25°C (68°F to 77°F). It is vital to keep the capsules in their original container, protected from light and moisture. Do not store the medication in areas of high humidity, such as a bathroom. For maximum safety, always store Alectinib 150mg Capsules in a secure, high location that is strictly out of the reach and sight of children and pets.

Safety Warnings for Alectinib 150mg Capsules

The administration of Alectinib 150mg Capsules requires monitoring for specific systemic toxicities. Hepatotoxicity (liver damage) can occur; liver function tests (ALT, AST, and bilirubin) must be monitored every two weeks for the first three months of treatment and monthly thereafter.

Interstitial Lung Disease (ILD)/Pneumonitis: Severe or life-threatening lung inflammation has been reported. Patients must be monitored for new or worsening respiratory symptoms (e.g., dyspnea, cough, fever), and the drug must be permanently discontinued if ILD is confirmed. Bradycardia (slow heart rate) and Severe Myalgia (muscle pain) with elevated creatine phosphokinase (CPK) are also known side effects. CPK levels should be monitored every two weeks during the first month of therapy.

Photosensitivity: Patients should be advised to avoid prolonged sun exposure and use broad-spectrum sunscreen, as the drug increases sensitivity to UV light. Alectinib 150mg Capsules can cause fetal harm (Pregnancy Category D); effective contraception is mandatory for both men and women during treatment and for at least 3 months after the final dose. By strictly following these professional guidelines and monitoring protocols, healthcare providers can safely maximize the therapeutic benefits of Alectinib 150mg Capsules.